Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
644 people get SCLN articles and Market Currents by email alert.
Get email alerts on SCLN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
SciClone On Solid Ground; Stock Is Cheap, And Large Investors Are BuyingPropThink • Thu, Nov 29, 2012
-
SciClone Pharmaceuticals: Promising Biotech With China ExposureDavid Zanoni • Tue, Sep 18, 2012 -
-
-
-
-
-
SciClone: Novamed Acquisition Helps, But Questions RemainGeneral Biologic • Fri, May 20, 2011
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
3 Stocks Upgraded On September 18 To ConsiderJorge Aura • Thu, Sep 20, 2012 -
4 Low-Debt Healthcare Stocks With Hefty Earnings TrendsZetaKap • Tue, Sep 4, 2012 -
-
-
-
-
-
Noteworthy Insider Buys And Sells In The Healthcare SectorGuruFundPicks • Fri, Jun 8, 2012 -
14 Outperforming Small Caps Undervalued By EPS TrendsKapitall • Wed, May 23, 2012
-
-
2 Biotech Stocks That Could Jump On Hepatitis C BreakthroughsRy Frank • Fri, Apr 27, 2012 -
8 Highly Liquid Healthcare Stocks Undervalued By EPS TrendsKapitall • Wed, Apr 18, 2012
-
-
SciClone Pharmaceuticals, Inc. Q4 2007 Earnings Call TranscriptThu, Mar 13, 2008
-
Marketwire (May 28, 2013)
-
Marketwire (May 16, 2013)
-
Marketwire (Apr 8, 2013)
-
Marketwire (Apr 1, 2013)
-
Marketwire (Apr 1, 2013)
-
Marketwire (Mar 22, 2013)
-
Marketwire (Mar 14, 2013)
-
Marketwire (Feb 22, 2013)
-
Marketwire (Feb 4, 2013)
-
Marketwire (Jan 30, 2013)
-
Marketwire (Jan 14, 2013)
-
Marketwire (Jan 7, 2013)
-
Marketwire (Dec 5, 2012)
-
Marketwire (Dec 4, 2012)
-
Marketwire (Nov 12, 2012)
-
Marketwire (Nov 9, 2012)
-
Marketwire (Sep 10, 2012)
SCLN vs. ETF Alternatives
Company Description
Currently, there's no company description for SCLN.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 4:20 PM SciClone Pharmaceuticals (SCLN) says it's entered into an agreement with Zensun Science & Technology granting SCLN a license and exclusive marketing and distribution rights to sell Neucardin, a treatment for intermediate to advanced chronic heart failure, in China, Hong Kong and Macau. Comment! [Healthcare, On the Move, Global & FX]
- Monday, April 1, 4:19 PM SciClone (SCLN): Q4 EPS of $0.03 misses by $0.09. Revenue of $33.4M misses by $1.9M. Shares -2.6% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Friday, March 22, 8:15 AM China-focused SciClone Pharmaceuticals (SCLN -0.9%) has appointed former Simcere Pharmaceutical Group Executive VP Hong Zhao as its CEO of operations in China. SciClone, which markets its flagship drug ZADAXIN in over 30 countries, said Mr. Zhao has a proven track record of delivering "strong top and bottom-line performance." Comment! [Healthcare, Global & FX]
-
Friday, February 22, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: EXEL +3%. DSLV +3%. BLT +2%. CY +2%. CZR +2%.
After-hours top losers: WETF -8%. SCLN -5%. MMSI -4%. ANF -3%. CHTR -3%. Comment! [On the Move] - Friday, February 22, 4:29 PM SciClone Pharmaceuticals (SCLN) says it will be restating financial statements for fiscal Q1, Q2, Q3 of 2011 as well as Q2 and Q3 in 2012 to account for accounting errors within its NovaMed subsidiary in China. The restatement primarily relates to accounting errors over the timing of Pfizer product revenue recognition and the recognition of product return reserves for its Aggrastat anticoagulant drug. SCLN acquired NovaMed in April 2011. Shares -6% AH. 1 Comment [Healthcare, Earnings]
- Monday, January 7, 2:52 PM SciClone Pharmaceuticals (SCLN +0.5%) updates its 2013 outlook, now expecting an initial EPS of $0.66 - $0.72 per share on revenues of between $150M - $155M. Analysts are looking for the company to earn $0.65 on revenue of around $152M. 1 Comment [Healthcare]
-
Monday, November 12, 2012, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%.
After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER -4.4%. GME -4.1%. MWE -3.7%. Comment! [On the Move] - Friday, November 9, 2012, 12:45 PM Midday top 10 gainers: HWG +66%. KIPS +41%. KYAK +27%. ZIP +25%. SQNM +22%. UBNT +19%. DGIT +17%. SQI +16%. CYTX +16%. ISIS +15%. Midday top 10 Losers: GRPN -27%. DTSI -26%. SCLN -24%. IDN -23%. RNDY -21%. III -17%. ADEP -17%. OSG -17%. STRA -16%. PTIX -15%. Comment!
- Friday, November 9, 2012, 6:21 AM SciClone Pharmaceuticals (SCLN): Q3 EPS of $0.20 misses by $0.01. Revenue of $40.6M (+8.8% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Thursday, August 9, 2012, 2:31 PM SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street estimates late yesterday. Total revenue jumped 22% Y/Y, helped by a 27% increase in sales of its drug Zadaxin, plus revenue growth from its primary care and oncology businesses in China and positive synergies from its recent takeover of NovaMed Pharmaceuticals. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, August 8, 2012, 4:06 PM SciClone Pharmaceuticals (SCLN): Q2 EPS of $0.20 beats by $0.02. Revenue of $40.3M (+21.8% Y/Y) in-line. Shares +0.4% AH. (PR) Comment! [Earnings, Healthcare]
- Wednesday, August 8, 2012, 12:10 AM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX Comment! [Earnings]
- Tuesday, August 7, 2012, 5:35 PM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX 2 Comments [Earnings]
- Wednesday, July 11, 2012, 9:48 AM SA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at $2.65-$3.80. These include: the failure of the firm's Zadaxin drug, its lead product, in multiple Phase III studies for various uses; probable price reductions in China, SciClone's main source of revenue; and an SEC investigation into bribery in the country. Shares -5.4% to $6.50. Comment! [Healthcare, On the Move]
- Wednesday, May 9, 2012, 5:10 PM SciClone Pharmaceuticals (SCLN): Q1 EPS of $0.15 beats by $0.04. Revenue of $39.2M (+81% Y/Y) beats by $2M. Shares +1.7% AH. (PR) Comment! [Earnings, Healthcare]
-
Monday, April 9, 2012, 9:05 AM
Premarket gainers: AOL +35%. GOLD +7%. SCLN +4%.
Losers: MOH -22%. HOGS -11%. OPTR -5%. RDN -4%. AVP -4%. ALU -4%. DRYS -3%. S -3%. X -3%. Comment! [On the Move]
-
Kapitall
Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Margins $SCLN $WCRX http://seekingalpha.com/a/ui5n - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Joe Springer
#biotech #pharma #stocks $VNDA $LLY $PPHM $GHDX $SCLN $AMRN $CRTX $NVS Vanda looks like a buy here: http://seekingalpha.com/a/h3pb - View all 0 replies
-
- View all 0 replies
-
Joshua Hayes
Four Stocks Hitting New Highs In A Weak Tape http://seekingalpha.com/a/e1xn CAMP SCLN SYPR INOD - View all 0 replies
-
- View all 0 replies
-
Michael Kudrna
Day Trading Radar and Market Commentary for Friday $GLUU $AKRX $ELGX $SCLN http://bit.ly/nautH1/ - View all 0 replies
LATEST REPLIES